Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 775-782

  Hida, Toyaki ^a   Leyton, Julius ^a   Makheja, Amar N ^b   Ben Av, Pazit ^c   Hla, Tim ^c   Martinez, Alfredo ^a   Mulshine, Jim ^a   Malkani, Sabrina ^a   Chung, Philip ^a   Moody, Terry W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c HOLLAND LABORATORY   (United States)

Author keywords

Cyclooxygenase 2; Non small cell lung cancer; NSAIDs; Proliferation; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; IBUPROFEN; INDOMETACIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL ESTER; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR CELLS, CULTURED;

EID: 14444267770     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Minna JD, Sekido Y, Fong KM and Gazdar AF: Molecular biology of Lung Cancer. In: Principles and Practice in Oncology, VT DeVita, S. Hellman and SA Rosenberg, Eds JP Lippincott, Philadelphia, 849-857, 1997.
2. Siegfried JM and Owens SM: Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res 48: 4976-4981, 1988.
3. Moody TW, Zia F, Brenneman D, Fridkin M, Davidspn A and Gozes I: A VIP antagonist inhibits the growth of non-small cell lung cancer. Proc Natl Acad Sci USA 90: 4345-4349, 1993.
4. Imanishi K, Yamaguchi K, Kuranami M, Kyo E, Hozumi T and Abe K: Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-α monoclonal antibody. J Natl Cancer Inst 81: 220-223, 1989.
5. Hunter T and Cooper JA: Protein tyrosine-kinases. Ann Rev Biochem 54: 897-930, 1985.
6. Schlessinger J: Allsoteric regulation of the epidermal growth factor receptor kinase. J Cell Biol 103: 2067-2072, 1986.
7. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
8. Birrer MJ, Alani R, Cuttitta F, Preis LH, Sabichi AL, Sanders DA, Siegfried JM, Szabo E and Brown PH: Early events in the neoplastic tranformation of respiratory epithelium. Journal of the National Cancer Institute Monographs No 13: 31-37, 1992.
9. Lee M, Draoui M, Zia F, Gazdar AF, Oie H, Tarr C, Bellot F, Kris R, and Moody TW: Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. JNCI Monographs, 13: 117-123, 1992.
10. Dewitt DL: Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochem Biophys Acta 1083: 121-134, 1991.
11. Hubbard WC, Alley MC, Gray GN, Green KC, McLemore TL, and Boyd MR: Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 49: 826-832, 1989.
12. Avis IM, Jett M, Boule T, Vos MD, Moody T, Treston AM, Martinez A, and Mulshine JL: Growth control of lung cancer by interruption of 5-Lipoxygenase-mediated growth factor signaling. J Clin Inves 97: 806-813, 1996.
13. Dewitt DL, and Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412-1416, 1988.
14. Dewitt DL, El-Harith EA, Kremer SA, Andrews MJ, Yao EF, Armstrong RL, and Smith WL: The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthase. J Biol Chem 265: 5192-5198, 1990.
15. Yokoyama C and Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 165: 888-894, 1989.
16. Xie W, Robertson DL and Simmons DL: Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. Drug Devel Res 25: 249-265, 1992.
17. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Takato MM: Suppression of intestinal polyposis in Ape 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996.
18. Smith WO and Marnett LJ: Prostaglandin endoperoxide synthases. Metal Ions Biol Syst 30: 163-199, 1994.
19. Greenberg ER, Baron JA, Freeman DHJ, Mandel JS and Haile R: Reduced risk of large-bowel adenomas among aspirin users: the polyp prevention study group. J Natl Cancer Inst 85: 912-916, 1993.
20. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascheno A and Willett WC. Aspirin use and the risk for colorectal. Cancer Res 54: 2390-2397, 1994.
21. Thun MJ, Namboodin MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
22. Thun MJ, Namboodin M, Calle E, Flanders W and Heath CJ: Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327, 1993.
23. Hubbard WC, Litterist CL, Liu MC, Bleecker ER, Eggleston JC, McLemore TL and Boyd MR: Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinomas and normal human lung by capillary gas chromatography-negative ion chemical ionization mass spectrometry. Prostaglandins 32: 889-906, 1986.
24. Lau SS, McMahon JB, McMenamin HG, Schuller HM and Boyd, MR: Metabolism of arachidonic acid in human lung cancer cell lines. Cancer Res 47: 3757-3762, 1987.
25. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH and Minna JD: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45: 2913-2923, 1985.
26. Bailey JM, Bryant RW, Feinmark SJ and Makheja AN: Differential separation of thromboxanes from prostaglandins by one and two-dimensional thin layer chromatography. Prostaglandins 13: 479-492, 1977.
27. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Bioc 18: 5294-5299, 1979.
28. Davis L, Dibner M and Battey JF: Basic Methods in Molecular Biology. Elsevier NY, 1986.
29. Hla T and Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
30. Ebina M, Steinberg SM, Mulshine JL and Linnoila RI: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non- small cell lung cancer. Cancer Res 54: 2496-2503, 1994.
31. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mikai S, Asai K, Kimura S, Kata H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
32. Mahmoud S, Staley J, Taylor J, Bogden A, Moreau JP, Coy D, Avis I, Cuttitta F, Mulshine J and Moody TW: (Psi13,14)Bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo. Cancer Res 51: 1798-1802, 1991.
33. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E and Kelloff, G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D.L.-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562-2568, 1990.
34. Reddy BS, Tokumo K, Kulkami N, Aligia C, and Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019-1023, 1992.
35. Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
36. Winde G, Gumbinger HG, Oswald H, Kemper F and Bunte H: The NSAID sulindac reverse rectal adenomas in colectomized patients with familial adenomatous polyposis clinical results of a dose finding on rectal sulindac administration. Int J Colorectal Dis 8: 13-17, 1993.
37. Waddell WR and Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983.
38. Waddell WR, Gasner GF, Cense EJ and Loughry, RW: Sulindac for polyposis of the colon. Am J Surg 157: 175-178, 1989.
39. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H and Gazdar A: Lung carcinoid cell lines have bombesin-like peptides and EGF receptors. J Cellular Biochemistry 43: 139-147, 1990.
40. Murakami M, Matsumoto R, Austen KF and Arm JP: Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 269: 22269-22275, 1994.
41. Reddy ST and Herschman HR: Ligand-induced prostaglandin requires expression of TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 269: 15473-15480, 1994.
42. Morita I, Schindler M, Regier MK, Otto JC, Hori T, Dewitt, DL and Smith WL: Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 270: 10902-10908, 1995.
43. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M, Prasit P, Rasori R, Riendeau D, Roy P, Tagari P, Vickers P, Wong E and Rodger IW: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. The Journal of Pharmacology and Experimental Therapeutics 274: 1531-1537, 1995.
44. Futaki N, Yoshikawa K, Hamaska Y, Arai I, Higuchi S, lizuka H, and Otomo S: NS-398 A novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24: 105-110, 1993.
45. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S and Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47: 55-56, 1994.
46. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR and Giardiello FM: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109: 994-998, 1995.
47. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
48. Duperron C and Castonguay A: Inhibition of lung tumorigenesis by aspirin in A/J mice. Cancer Res 36: 592, 1996.
49. DeWitt D and Smith WL. Yes, but do they still get headaches?. Cell, 83: 345-348, 1995.
50. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach, S, and DuBois RN: Up regulation of cycloxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
51. Kargman SL, O'Neill GP, Vicker PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.